维生素涨价不是昙花一现

Core Viewpoint - The recent surge in vitamin prices is primarily driven by proactive supply contraction rather than geopolitical conflicts, indicating that the vitamin industry has entered the early stage of a cyclical recovery [6][32]. Group 1: Price Surge Dynamics - Since the outbreak of the Middle East conflict in late February, the vitamin market has experienced a strong price increase, particularly for Vitamin A and E, due to supply pressures in Europe [2][3]. - Vitamin A prices rose from 60.5 yuan/kg to 110 yuan/kg, an increase of 82%, while Vitamin E prices increased from 57.5 yuan/kg to 97.5 yuan/kg, a rise of 70% [2]. - The core reason for the price increase is not the geopolitical situation but rather a deliberate reduction in supply by major producers [6][14]. Group 2: Supply Chain and Market Structure - The vitamin industry is characterized by a high concentration of production, with major players like DSM and BASF dominating the market, which gives them significant pricing power [11][14]. - The largest application of vitamins is in animal feed, accounting for 80% of usage, with a low cost impact on feed, making downstream demand relatively insensitive to price changes [9][10]. - Following a previous price war, major producers have shifted strategies from market share competition to proactive supply contraction to restore profitability [14][15]. Group 3: Future Supply and Market Outlook - The potential for a rapid recovery in supply over the next 1-2 quarters is low due to several factors, including the time required for European production facilities to restart and the lengthy process of building new capacity [19][22]. - The proactive supply control strategies employed by producers are likely to continue in the short term, as many products remain unprofitable [23]. - The current low inventory levels and tight supply conditions are a direct result of these strategies, suggesting that the price increase may persist in the near term [16][32]. Group 4: Investment Opportunities - Companies with strong pricing power and solid earnings visibility, such as New Hope Liuhe and Zhejiang Medicine, are positioned well in the current market environment [27]. - The focus should be on firms that can benefit from the price increases while maintaining low valuations, as well as those in sectors currently experiencing losses that may see price recovery [28].